ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

Japan nears homegrown vaccine with Daiichi Sankyo Phase 3 trials

Shionogi eyes enough COVID shots for 60m people a year

TOKYO -- Daiichi Sankyo plans to begin Phase 3 clinical trials for its coronavirus vaccine this autumn with the aim of bringing it to the public in 2022, finally pushing forward Japan's effort to locally develop COVID-19 shots.

A few other Japanese drugmakers are also making progress in vaccine development, including Shionogi, which says it would be able to supply enough doses for 60 million people a year if a reduced dose proves to be as effective as the previously proposed amount.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more